Scholars@Duke
Maggie L DiNome

Maggie L DiNome

Professor of Surgery
Surgical Oncology
4101 Macon Pond Road, Raleigh, NC 27607

Scholarly Works - Conferences

Abstract P2-12-01: Survival Outcomes after Pathologic Complete Response with Neoadjuvant Endocrine Therapy vs. Neoadjuvant Chemotherapy

Conference Clinical Cancer Research · June 13, 2025 AbstractBackground: Neoadjuvant systemic therapy has emerged as the standard of care for many patients with breast cancer potentially leading to surgical downstaging and providing insight into treatment resp ... Full text Cite

Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy.

Conference Ann Surg Oncol · December 2024 BACKGROUND: Axillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the Alliance A011202 trial evaluating the oncol ... Full text Link to item Cite

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.

Conference Ann Surg Oncol · November 2024 BACKGROUND: Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described ... Full text Link to item Cite

Abstract PO1-10-01: Racial/Ethnic Disparities in Rates of Pathological Complete Response and Survival in Patients with Inflammatory Breast Cancer

Conference Cancer Research · May 2, 2024 AbstractRadiation Therapy Toxicities and Survival Outcomes in Monoallelic ATM Variant Carriers with Non-Metastatic Breast Cancer: A Retrospective Analysis Rayan Bensenane1 MD, Arnaud Beddok1,2,3 MD, Nadine A ... Full text Cite

Triple Negative Breast Cancer in Older Patients: Does Sentinel Lymph Node Biopsy Guide Therapy?

Conference JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS · November 2023 Link to item Cite

Breast cancer staging for patients with “low risk” disease: Are they all the same?

Conference Journal of Clinical Oncology · June 1, 2023 6584 Background: Studies have shown that a low (<11) Oncotype DX recurrence score (RS) is associated with better survival outcomes. RS is currently included in the AJCC prognostic staging criteria. Not all patients with a low ... Full text Cite

Abstract P3-05-20: Low 21-Gene Recurrence Score Is Not Associated with a High Axillary Nodal Burden in Post-Menopausal Women Presenting with a Clinically Negative Axilla

Conference Cancer Research · March 1, 2023 AbstractBackground: The predictive and prognostic value of the 21-gene recurrence score (RS) has emphasized the importance of tumor biology and minimized the credence of a limited (1-3 positive) nodal burden ... Full text Cite

Abstract P1-06-02: The effect of race on pathologic complete response rates and overall survival in patients with triple negative breast cancer

Conference Cancer Research · March 1, 2023 AbstractIntroduction: Despite the recent overall improvement in survival for patients with breast cancer, racial disparities in outcomes persist. While studies have demonstrated that socioeconomic factors an ... Full text Cite

ShouldStage IA Breast Cancerbe Expanded?

Conference ANNALS OF SURGICAL ONCOLOGY · March 2023 Link to item Cite

The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions.

Conference Ann Surg Oncol · October 2022 BACKGROUND: Multiple studies have demonstrated a link between obesity and breast cancer; however, the potential association between obesity and atypical high-risk breast lesions has not been well characterized. We sought to evaluate the characteristics and ... Full text Link to item Cite